Vascular Dementia - Pipeline Insight, 2026

DelveInsight's, "Vascular Dementia - Pipeline Insight, 2026" report provides comprehensive insights about 6+ companies and 6+ pipeline drugs in Vascular Dementia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered:

• Global coverage

Vascular Dementia: Understanding

Vascular Dementia: Overview

Vascular dementia is a prevalent cause of major neurocognitive disorder (MND) in older adults, characterized by cognitive decline in various domains and functional independence. It is primarily linked to cardiovascular risk factors like smoking, hypertension, hyperlipidemia, diabetes, and atrial fibrillation. Diagnosis involves a comprehensive evaluation, including history-taking, physical, and neurologic examinations, with neuroimaging enhancing diagnostic accuracy. Currently, treatment for vascular dementia focuses on supportive care due to the lack of approved disease-modifying medications. Vascular dementia differs from other MNDs in that it results from cerebrovascular pathologies, rather than neurodegenerative proteinopathies. The link between vascular events and cognitive decline may be subtle. Vascular risk factors lead to cerebrovascular disease, causing brain injury and disrupting cognitive networks, culminating in vascular dementia. Research suggests vascular dementia and Alzheimer's frequently co-occur, with cerebrovascular dysfunction exacerbating Alzheimer's pathology and vice versa.

Vascular dementia presents a range of signs and symptoms that can vary depending on the affected brain areas and the extent of damage. These symptoms may manifest suddenly after a major stroke or progress gradually over time. Early signs can include slowness of thought, difficulty with planning, changes in mood or behavior, and problems with memory and language. As the condition advances, individuals may experience significant slowness of thought, confusion, and memory loss, difficulty finding the right words, personality changes, depression, balance issues, incontinence, and challenges with daily activities. Notably, vascular dementia symptoms can overlap with those of Alzheimer's disease, and the progression of symptoms is often linked to the location and severity of brain damage caused by reduced blood flow and oxygen delivery to the brain.

Treatment for vascular dementia focuses on managing underlying cardiovascular risk factors and providing supportive care. Medications may be prescribed to control blood pressure, cholesterol, triglycerides, diabetes, and prevent blood clots. Lifestyle changes, such as a healthy diet, regular exercise, smoking cessation, and limiting alcohol intake, are also important. Cholinesterase inhibitors and antidepressants can help manage symptoms like cognitive decline and depression. Cognitive therapy, speech therapy, and therapies to promote well-being, such as music therapy and outdoor activities, may also be beneficial. However, there is currently no cure for vascular dementia, and the disease progresses over time, often requiring increasing levels of care.

"Vascular Dementia - Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Vascular Dementia pipeline landscape is provided which includes the disease overview and Vascular Dementia treatment guidelines. The assessment part of the report embraces, in depth Vascular Dementia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Vascular Dementia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights:

• The companies and academics are working to assess challenges and seek opportunities that could influence Vascular Dementia R&D. The therapies under development are focused on novel approaches to treat/improve Vascular Dementia.

Vascular Dementia Emerging Drugs Chapters

This segment of the Vascular Dementia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II/III, II, I, preclinical and discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Vascular Dementia Emerging Drugs

• Apabetalone: Resverlogix Corporation

Apabetalone is the world leader in a new class of drugs designed to regulate disease-associated proteins. Traditional therapeutics target a single, disease-causing factor with the intention of treating or curing complex and chronic illnesses. By inhibiting the action of bromodomain and extraterminal domain (BET) proteins, apabetalone positively affects multiple disease-causing biological processes, leading to a new paradigm shift in the treatment of chronic disease. Apabetalone has a unique mechanism of action, working at the level of "transcription". As a selective inhibitor of the BET family of proteins, apabetalone has the ability to normalize dysregulated epigenetics that lie at the heart of many chronic diseases. Apabetalone blocks the action of BET proteins, bringing the increased production of dysregulated proteins back down to healthier levels. Apabetalone can be administered as a twice-daily tablet. Most importantly, apabetalone has proven to be safe. Due to its unique epigenetic mechanism, the company continues to discover more ways that apabetalone can benefit patients across a broader range of chronic diseases, including neurodegenerative diseases, peripheral artery disease, and a number of rare diseases. Currently, the drug is in the Phase III stage of its development for the treatment of VaD.

• ACP-01: Hemostemix

ACP-01 (VesCell) is an investigational autologous angiogenic cell therapy developed by Hemostemix for the treatment of vascular dementia and vascular cognitive impairment associated with impaired cerebral blood flow. ACP-01 is derived from the patient's own blood and contains angiogenic cell precursors that are being studied for their potential to promote angiogenesis, improve microvascular circulation, and enhance blood flow to ischemic brain tissue. Hemostemix is advancing ACP-01 under a Phase I vascular dementia research program designed to evaluate its safety and potential effects on cognitive and neurological outcomes, with the company collaborating with Firefly Neuroscience to assess brain activity using its Brain Network Analytics (BNA(TM)) platform. In October 2025, Hemostemix filed an ethics application for the Phase I study of ACP-01 in vascular cognitive impairment and dementia..

Vascular Dementia: Therapeutic Assessment

This segment of the report provides insights about the different Vascular Dementia drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Vascular Dementia

There are approx. 6+ key companies which are developing the therapies for Vascular Dementia. The companies which have their Vascular Dementia drug candidates in the most advanced stage, i.e. Phase III include, Resverlogix Corporation.

• Phases

DelveInsight's report covers around 6+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Vascular Dementia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous
• Subcutaneous
• Oral
• Intramuscular
• Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal antibody
• Small molecule
• Peptide
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Vascular Dementia: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Vascular Dementia therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Vascular Dementia drugs.

Vascular Dementia Report Insights

• Vascular Dementia Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Vascular Dementia Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions:

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Vascular Dementia drugs?
• How many Vascular Dementia drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Vascular Dementia?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Vascular Dementia therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Vascular Dementia and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Resverlogix Corporation
• Hemostemix
• Can-Fite Biopharma

Key Products

• Apabetalone
• ACP-01

Piclidenoson